Given the similarity between AML and CML in terms of oncogene-driven mechanisms, it is likely that the overexpression of SNAI2 in AML plays a similar role in promoting resistance and cell proliferation to standard AML therapies. Here, SNAI2 is linked to acute myeloid leukemia.